NEW

Legent Imaging Increases Revenue, Decreases Rejected Claims

Konica Minolta Healthcare Americas, Inc. announced today the implementation of Exa® PACS/RIS/Billing and the company’s Revenue Cycle Management (RCM) solution, provided by All Covered, Konica Minolta Business Solutions U.S.A., Inc.'s IT Services Division, at Legent...

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker has unveiled its Q Guidance System for spine applications. The system combines new optical tracking options provided by a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Spine Guidance Software to deliver more surgical...

FDA Approves Gadopiclenol Injection for U.S. Market

Bracco Diagnostics Inc., the United States (U.S.) subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic...

Fujifilm Upgrades ASGE’s Institute for Training and Technology with State-of-the-Art Endoscopic Imaging Solutions

FUJIFILM Healthcare Americas Corporation and the American Society for Gastrointestinal Endoscopy (ASGE) announce that ASGE has equipped its Chicago-based Institute for Training and Technology (IT&T) Advanced Bioskills Laboratory and Simulation Center with 16 of...

Study Demonstrates Effectiveness of CorPath GRX Neurovascular System

Corindus, a Siemens Healthineers Company and a developer of precision vascular robotics, has presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System. The data represents a milestone in the company’s commitment to extending precision robotics into neurovascular treatment, according to a press release.

The prospective, single-arm, international, multi-center, non-inferiority study is the world’s first trial on robotic-assisted neurovascular aneurysm embolization. Principal Investigator Michel Piotin, MD, Ph.D., head of the interventional neuroradiology department at the Rothschild Foundation Hospital in Paris, presented the results as part of the AI & New Innovations session at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Nice, France.

Key findings of the study showed:

  • The CorPath GRX Neurovascular System demonstrated 94 percent technical success. It achieved the primary effectiveness goal, which was defined as successful completion of the robotic-assisted endovascular procedure absent of any unplanned conversion to a manual procedure.
  • The CorPath GRX Neurovascular System demonstrated 95.7 percent clinical success. It achieved the primary safety goal, defined as patients treated without intra- and periprocedural adverse events, including target aneurysmal rupture, vessel perforation or dissection, and thromboembolic event with neurological decline within 24 hours post-procedure or hospital discharge, whichever occurred first.
  • 64.5 percent of subjects achieved Class I status, meaning complete obliteration of the aneurysm, on the Raymond-Roy Occlusion Classification (RROC), the standard for evaluating aneurysm occlusion.
  • 78.2 percent of subjects showed no clinical symptoms post-procedure, achieving a 0 on the Modified Rankin Scale (mRS) for Neurologic Disability. The remaining 21.8 percent of subjects had an mRS of 1 or 2.

“Neurovascular intervention demands extreme precision to achieve optimal clinical outcomes,” said Piotin. “The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels. I am honored to have participated in a groundbreaking study that may lead to an entirely new treatment paradigm in neurovascular care.”

The study included 117 patients from 10 clinical sites in six different countries. It also included a wide range of aneurysms, representing a diverse collection of cases with different locations, sizes and morphology characteristics. The health care facilities that treated the trial participants will follow them for 180 days to monitor extended, long-term outcomes.

“The work of our clinical partners on this study marks an early step toward truly transformative change in neurovascular intervention,” said Dr. Raymond Turner, chief medical officer, neuroendovascular at Corindus. “By incorporating robotic platforms in this space, we are paving the way for remote interventional procedures in the future that will connect patients to specialized interventionalists for treatment, regardless of location. Validating clinical evidence, such as this study, will serve as the foundation for that transformation.”

The CorPath GRX System is the first FDA-cleared and CE Marked medical device for percutaneous coronary and vascular procedures. It earned CE Mark for neurovascular procedures, and health care facilities outside of the U.S. currently utilize the platform for neurovascular interventions. The company is currently pursuing additional regulatory clearances for the neurovascular indication.

To learn more about CorPath GRX, please visit www.corindus.com.

Previous

Next

Submit a Comment

Your email address will not be published.